HomeCompareCKHGY vs ABBV

CKHGY vs ABBV: Dividend Comparison 2026

CKHGY yields 1.41% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CKHGY wins by $15.30M in total portfolio value· pulled ahead in Year 5
10 years
CKHGY
CKHGY
● Live price
1.41%
Share price
$125.19
Annual div
$1.76
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.41M
Annual income
$13,555,792.20
Full CKHGY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CKHGY vs ABBV

📍 CKHGY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKHGYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKHGY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKHGY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKHGY
Annual income on $10K today (after 15% tax)
$119.60/yr
After 10yr DRIP, annual income (after tax)
$11,522,423.37/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CKHGY beats the other by $11,501,367.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKHGY + ABBV for your $10,000?

CKHGY: 50%ABBV: 50%
100% ABBV50/50100% CKHGY
Portfolio after 10yr
$7.75M
Annual income
$6,790,281.98/yr
Blended yield
87.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CKHGY
No analyst data
Altman Z
1.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKHGY buys
0
ABBV buys
0
No recent congressional trades found for CKHGY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKHGYABBV
Forward yield1.41%3.06%
Annual dividend / share$1.76$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$15.41M$102.3K
Annual income after 10y$13,555,792.20$24,771.77
Total dividends collected$15.24M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CKHGY vs ABBV ($10,000, DRIP)

YearCKHGY PortfolioCKHGY Income/yrABBV PortfolioABBV Income/yrGap
1$10,981$281.41$11,550$430.00$569.00ABBV
2$12,328$577.62$13,472$627.96$1.1KABBV
3$14,403$1,212.02$15,906$926.08$1.5KABBV
4$18,058$2,646.78$19,071$1,382.55$1.0KABBV
5← crossover$25,524$6,202.71$23,302$2,095.81+$2.2KCKHGY
6$43,699$16,387.86$29,150$3,237.93+$14.5KCKHGY
7$99,200$52,442.59$37,536$5,121.41+$61.7KCKHGY
8$328,667$222,522.02$50,079$8,338.38+$278.6KCKHGY
9$1,729,710$1,378,036.94$69,753$14,065.80+$1.66MCKHGY
10$15,406,582$13,555,792.20$102,337$24,771.77+$15.30MCKHGY

CKHGY vs ABBV: Complete Analysis 2026

CKHGYStock

Capitec Bank Holdings Limited, through its subsidiaries, provides various banking products and services in South Africa. The company operates through three segments: Retail Bank, Business Bank, and Insurance. It offers transactional banking services; fixed and tax-free savings, and call and notice deposits; term loans, credit facilities, mortgage loans, overdrafts, instalment sales and leases, credit and debit cards, and access facilities; rental finance; payment services; and merchant services, as well as credit and life insurance products. The company also provides treasury products comprising foreign exchange spot trades and foreign exchange forward contracts; and internet banking and mobile banking services. It operates approximately 853 branches; and 2,863 automated teller machines, dual note recyclers, and coin and note recyclers. The company was incorporated in 1999 and is based in Stellenbosch, South Africa.

Full CKHGY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CKHGY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKHGY vs SCHDCKHGY vs JEPICKHGY vs OCKHGY vs KOCKHGY vs MAINCKHGY vs JNJCKHGY vs MRKCKHGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.